SERVIFY
14.6.2022 14:32:06 CEST | Business Wire | Press release
Servify , a global AI-driven product ownership experience platform, announced its partnership with Samsung Electronics Canada to roll out its premium protection plan for corporate devices: Samsung Care+ for Business. The service is designed exclusively for nationwide enterprises and government customers.
After a successful launch last year in the US market where the Samsung B2B program has been well received, the partnership is now extending into the Canadian market which is poised to see more than 90 percent of Canadians becoming digital natives by 2023.*
As remote work went from “new normal” to “status quo” over the last two years, enterprises have witnessed an increased dependency on mobile devices for work and are concerned about business continuity challenges. To solve this, Samsung Care+ for Business is set to deliver a complete solution for device protection, thereby maximizing business productivity.
Servify will be responsible for overall management and administration of the program, together with system integration with Samsung’s authorized repair partners. Leveraging Servify’s post-sales product ownership experience platform, Samsung is poised to deliver protection with a combined coverage term of up to 3 years.**
Benefits for Enterprises |
|
|
|
“We are thrilled to have partnered with Samsung for their B2B program in Canada. Our ongoing alliance with Samsung covers several regions including US, Eastern Europe, KSA, UAE and India which reiterates the trust Samsung has in our capabilities, ” said Sreevathsa Prabhakar , Founder of Servify .
“Today’s businesses are making significant investments in devices, and we believe it is our job to help them be prepared for any issues with seamless, automated device management tools. Samsung Care+ for Business, enabled by Servify’s platform and underpinned by Samsung’s authorized repair services for physical damage and liquid intrusion protection, will prove beneficial for businesses as they need to anticipate when devices are reaching end-of-life, determine if they are vulnerable to security breaches, and resolve a host of other issues before such issues create operational delays ,” said Steven Cull , Head of Mobile Product Management, Services and Strategy, at Samsung Canada .
Samsung Care+ for Business provides its customers a worry-free protection plan, guaranteed Samsung certified service and hassle-free process for claims and tech support.
* https://www.statista.com/topics/4865/internet-usage-in-canada/#dossierKeyfigures
** Manufacturer's limited warranty is 1 year, plus up to 2 years of extended warranty - for a total of up to 3 years warranty. Available on certain Samsung devices, including Galaxy XCover and Tab Active Series devices. For physical damage and liquid intrusion service requests, two (2) covered claims are allowed per each 12-month period during the duration of the Samsung Care+ for Business.
About Samsung
Samsung Electronics Canada inspires Canadians to reach their full potential through a transformative ecosystem of products and services that deliver innovation and distinct design to every aspect of their connected lives. The company is redefining the worlds of TVs, smartphones and wearable devices, tablets and digital appliances. In 2022, Samsung was ranked as one of Canada's "Most Reputable Companies" in Léger's Corporate Reputation Study. Dedicated to helping make a difference in the lives of Canadians, Samsung's award-winning corporate giving initiatives support public education and health-related issues in communities across the country. To discover more, please visit www.Samsung.ca .
About Servify
Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.
Additional information on Servify is available at www.servify.tech .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005582/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom